ASCO 2025 – 3SBio reveals what Pfizer got for its $1.25bn
Early data on SSGJ-707 in PD-L1-positive lung cancer spur comparisons against ivonescimab.
ASCO 2025 – vepdegestrant matches rival degraders
Any hopes of differentiation could come down to side effects.
ASCO 2025 – Dizal goes after the BTK leaders
DZD8586 shows some evidence that it can rescue BTK failures, but its precise role remains unclear.
ASCO 2025 – zilo-V adds a patient death to its tox tally
The second line shows no respite for Merck & Co's ROR1-targeting ADC.
Harmoni spoils Summit's pre-ASCO splash
Summit gatecrashes ASCO, but Harmoni shows no OS benefit and a large patient overlap.
ASCO 2025 – Braftovi breaks new ground
The Breakwater study hits on overall survival with "unprecedented" data.
ASCO 2025 preview – KRAS challengers assemble
Lilly, Merck & Co and Verastem could take on Amgen, Bristol and Revolution.
ASCO 2025 preview – Kura looks similar to Syndax
Meanwhile, Pfizer reckons it's found the right dose for its KAT6.
